SYGNIS AG / Key word(s): Quarter Results
2015-05-13 / 08:00
SYGNIS reports results for the first quarter 2015
– Two proprietary product lines succesfully launched
– Seven international sales and distribution agreements signed
– Revenues increased year-on-year by 19%
– Net loss reduced year-on-year by 13%
– Outlook 2015 confirmed
Madrid, Spain and Heidelberg, Germany, 13 May 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced its financial results for the first quarter of 2015, ended 31 March 2015.
In the first quarter of 2015, revenues increased by 19% to EUR76 thousand (Q1 2014: EUR64 thousand). As expected, in Q1 revenues were still at a lower level given the Company currently is still in the ramp-up phase after just having launched the first kits and started to build up its distribution network.
Operating loss improved by 13% to EUR721 thousand (Q1 2014: EUR811 thousand), mainly due to reduced operating expenses of EUR797 thousand (Q1 2014: EUR875 thousand).
Operating expenses included sales, general & administrative costs of EUR503 thousand as well as research & development costs of EUR307 thousand. The decrease of operating costs mainly resulted from lower personnel costs of EUR308 thousand, a reduction of 21% compared to the previous year period (Q1 2014: EUR390 thousand).
As of 31 March 2015, cash and cash equivalents amounted to EUR2.5 million (31 December 2014: EUR3.8 million). Total short term assets were EUR3.0 million (31 December 2014: EUR4.1 million).
Activities during the first quarter of 2015 were strongly focused on the further development of SYGNIS’ new product and commercialization strategy.
Successful first product launches: Over the first quarter 2015, SYGNIS launched two product lines based on the Company’s proprietary technologies covering three innovative new products.
The first product line, TruePrime(TM), covers a series of kits for whole genome amplification based on SYGNIS’ proprietary revolutionary TruePrime(TM) technology, processing multiple displacement amplifications (MDA) for use with various DNA or RNA species from a variety of samples for a multitude of applications. The first products are used for the primer-free amplification of entire genomes from single cells as well as for the amplification of DNA and entire genomes from various sample types and smaller sample volumes.
The second product line, SunScript(TM), covers a series of kits based on novel proprietary engineered reverse transcriptase (RT) to convert genetic information from RNA molecules back to DNA and is one of the most thermostable and fastest enzymes commercially available today.
Building commercialization capabilities: In parallel to its launch activities, the Company made enormous progress in expanding its sales and marketing capabilities by establishing a distribution network with industry leading partners in North America, Asia and Europe, covering the important regional markets such as Germany, France and the UK.
In addition, SYGNIS established its own online shop, where the products can be ordered directly. Furthermore, the Company presented and promoted its unique technologies and products at renowned scientific conferences in Europe and the U.S.
In April, Dr. Miguel-Antonio Viribay joined SYGNIS and assumed responsibility for the further development, implementation and execution of sales and marketing strategies as Vice President Sales and Marketing. In this newly created position, he will support and further enhance SYGNIS position as a leading provider of innovative products and technologies for DNA amplification and sequencing in growth markets, especially in Europe and the U.S.
Pilar de la Huerta, CEO and CFO of SYGNIS commented: “During the first quarter of 2015, we have strongly focused on expanding our product portfolio and on strengthening our commercialization capabilities. The effect of our efforts did not yet materialize into actual sales and revenues in the launch period over the recent months. However, this period has been essential for paving our way to accelerated growth and a successful future as a product company and as a leading supplier for products and enabling technologies for DNA amplification and sequencing, addressing high growth markets in molecular biology including NGS and single cell analysis.”
SYGNIS confirmed the outlook for fiscal year 2015 published on 29 April 2015.
The revenues in the fiscal year 2015 are dependent on the success of the market launch of our first own products and on revenue growth arising from the license agreement with QIAGEN for additional products based on SensiPhi(R). Furthermore, SYGNIS expects first revenues from the out-licensing of Double Switch. Depending on the success of these commercialization activities, revenues in 2015 were forecast at approximately EUR700 thousand, with a strong upside potential in 2016. The Company expects net losses to be significantly lower than in 2014.
The financial resources available as of 31 March 2015 and the expected cash inflow during the remaining fiscal year 2015 will provide SYGNIS with sufficient liquidity to cover the operating expenses until break-even, which is estimated to be in 2016.
The interim report for the first quarter, ended 31 March 2015, is available for download from the Company’s webpage at www.sygnis.com.
For further information please contact:
About SYGNIS AG: www.sygnis.com
Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi(R), licensed to an industry leading partner and two own product lines on the market: TruePrime(TM) based on its proprietary TruePrime(TM) technology for whole genome amplification and SunScript(TM) Reverse Transcriptase to convert genetic information from RNA molecules back to DNA. Both product lines are addressing key challenges in the fast growing fields of molecular biology and next generation sequencing applications.
This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###
2015-05-13 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Im Neuenheimer Feld 515|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart|
|End of News||DGAP News-Service|